# OnCo record cachexia-therapy (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/cachexia-therapy/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "cachexia-therapy" ;
  schema:name "Cachexia-directed therapy (GDF-15 blockade)"@en ;
  schema:description "Cachexia-directed therapy treats cancer wasting by blocking GDF-15, a hormone that rises in advanced cancer and acts on the brainstem to suppress appetite. Pfizer's antibody ponsegromab improved weight in a phase 2 trial and is in phase 2/3 in pancreatic cancer cachexia; whether weight gain translates into function is the open question."@en ;
  schema:url <https://onco.cc/technologies/cachexia-therapy/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06989437>, <https://clinicaltrials.gov/study/NCT05546476> ;
  onco:status "phase-3" ;
  onco:tag "frontier", "promising" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/nutrition-lifestyle/> ;
  onco:technologies <https://onco.cc/technologies/geriatric-assessment/>, <https://onco.cc/technologies/exercise-oncology/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:journals <https://onco.cc/journals/journal-of-cachexia-sarcopenia-and-muscle/> .